Please login to the form below

Not currently logged in
Email:
Password:

Celgene’s CEO Mark Alles is appointed as chairman

He succeeds Bob Hugin who is retiring from the pharma firm

Executive chairman Bob Hugin has decided to retire from Celgene after 19 years of service and will step down from the board of directors effective 5 February.

Hugin initially joined Celgene as its chief financial officer and then subsequently became chief operating officer and chief executive officer.

His successor will be Celgene’s current chief executive officer Mark Alles, who will remain as CEO along side his new position as the chairman of the board of directors.

Alles has been with Celgene since 2004, holding roles such as chief operational officer and executive vice president, global head of haematology and oncology.

Michael Casey, Celgene’s lead independent director, said: “Mark is a tremendous leader and the best person to guide Celgene into its next phase of significant growth.

“Through his strategic leadership as CEO, Celgene has advanced and expanded its portfolio of potentially life-changing medicines.”

6th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics